Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639911 | 1.00 | L3MBTL1 (0.67) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA | |
| SCHEMBL22639790 | 0.89 | POLB (0.72) | L3MBTL1SMN1; SMN2KMT2AMAPTTP53 | |
| SCHEMBL16370714 | 0.89 | L3MBTL1 (0.71) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA | |
| SCHEMBL16370581 | 0.89 | L3MBTL1 (0.71) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA | |
| SCHEMBL16370933 | 0.89 | L3MBTL1 (0.71) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA | |
| SCHEMBL22639857 | 0.89 | POLB (0.72) | L3MBTL1SMN1; SMN2KMT2AMAPTTP53 | |
| SCHEMBL16371024 | 0.89 | L3MBTL1 (0.71) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA | |
| Hydrochloric Acid SCHEMBL16371042 | 0.88 | MAPK1 (0.72) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA | |
| SCHEMBL4578170 | 0.83 | USP2 (0.83) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA | |
| SCHEMBL12834994 | 0.82 | USP2 (0.81) | L3MBTL1SMN1; SMN2KMT2AMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | L3MBTL1 715/4885SMN1; SMN2 2515/4885KMT2A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.